J
Jeff M. Michalski
Researcher at Washington University in St. Louis
Publications - 393
Citations - 24291
Jeff M. Michalski is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 73, co-authored 330 publications receiving 20977 citations. Previous affiliations of Jeff M. Michalski include American Urological Association & American Society for Radiation Oncology.
Papers
More filters
Journal ArticleDOI
Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
TL;DR: The 3D-CRT spares more normal tissues, yields higher chemical disease-free survival, and results in less treatment morbidity than SRT in treatment of stage T1-T2 prostate cancer.
Journal ArticleDOI
Imaging and Data Acquisition in Clinical Trials for Radiation Therapy.
Thomas J. Fitzgerald,Maryann Bishop-Jodoin,David S Followill,James M. Galvin,Michael V. Knopp,Jeff M. Michalski,Mark A. Rosen,Jeffrey D. Bradley,Lalitha K. Shankar,F. Laurie,M. Giulia Cicchetti,Janaki Moni,C. Norman Coleman,James A. Deye,Jacek Capala,Bhadrasain Vikram +15 more
TL;DR: Integration of imaging and radiation oncology data acquisition, review, management, and archive strategies are essential for trial compliance and future research.
Journal ArticleDOI
ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
Jeff M. Michalski,Mack Roach,Gregory S. Merrick,Mitchell S. Anscher,David C. Beyer,Colleen A. Lawton,W. Robert Lee,Alan Pollack,Seth A. Rosenthal,Srinivasan Vijayakumar,Peter R. Carroll,Peter R. Carroll +11 more
Journal ArticleDOI
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
Amar U. Kishan,Xiaoyan Wang,Yilun Sun,Tahmineh Romero,Jeff M. Michalski,Ting Martin Ma,Felix Y. Feng,Howard M. Sandler,Michel Bolla,Philippe Maingon,T. de Reijke,An Neven,Allison Steigler,James W. Denham,David Joseph,Abdenour Nabid,Nathalie Carrier,Luis Souhami,Matthew R. Sydes,David P. Dearnaley,Isabel Syndikus,Alison Tree,Luca Incrocci,Wilma D. Heemsbergen,Floris J. Pos,Almudena Zapatero,Jason A. Efstathiou,A. Guerrero,Ana Alvarez,Carmen González San-Segundo,Xavier Maldonado,Michael Xiang,Matthew Rettig,Robert E. Reiter,Nicholas G. Zaorsky,Wee Loon Ong,Robert T. Dess,Michael L. Steinberg,Nicholas G. Nickols,Soumyajit Roy,Jorge Alberto Barrios Garcia,Daniel E. Spratt +41 more
TL;DR: In this article , the relative benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer are unknown.
Journal ArticleDOI
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Patrick A. Kupelian,Patrick A. Kupelian,Howard D. Thames,Larry B. Levy,Eric M. Horwitz,Alvaro Martinez,Jeff M. Michalski,Thomas M. Pisansky,Howard M. Sandler,William U. Shipley,Michael J. Zelefsky,Anthony L. Zietman,Deborah A. Kuban +12 more
TL;DR: Independent of tumor stage, radiation dose, failure definition, and follow-up parameters, the year in which RT was performed was an independent predictor of outcomes.